We are live on ! Find out more

Fennec Pharmaceuticals

FENC

Market cap $384M

10.96 USD

-0.34

3.01%

At close Updated Sep 11, 4:00 PM EDT

1 day

-3.01%

5 days

-11.97%

1 month

-14.24%

3 months

23.84%

6 months

37.52%

Year to date

42.71%

1 year

21.37%

5 years

26.27%

10 years

-8.67%

About: Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Employees: 35

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 75%

Negative 0%

Zacks Investment Research

Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?

Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript

Adherex Technologies Q2 Earnings Call Highlights

Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise.

Adherex Technologies Q2 Earnings Call Highlights

Zacks Investment Research

Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates

Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.

Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2026 financial results before the opening of the U.S. financial markets on Tuesday, August 11, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

Zacks Investment Research

Is the Options Market Predicting a Spike in Adherex Technologies Stock?

Investors need to pay close attention to FENC stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Adherex Technologies Stock?

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 15,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 22, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.

Fennec Announces Results of Annual Meeting

Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter

Fennec Pharmaceuticals NASDAQ: FENC executives outlined the company's commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference.

Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter

See News Rankings

Price charts implemented using Lightweight Charts™